On October 25, 2019, Juelsgaard Clinic students Mondee Lu and Annie Wanless submitted an amicus curiae brief on behalf of eight HIV research, policy, and advocacy organizations: Treatment Action Group (TAG), AIDS Action Baltimore (AAB), The Foundation for AIDS Research (“amfAR”), AVAC: Global Advocacy for HIV Prevention, Health GAP (Global Access Project), Housing Works, The SERO Project, and the U.S. PLHIV Caucus in this antitrust case in the Northern District of California. The brief urged the court to deny Gilead’s and the other defendants’ motions to dismiss the plaintiffs’ Complaint against them for anticompetitive actions that kept generic HIV drugs out of the market, kept prices artificially high, and harmed Americans who need HIV drugs for treatment and prevention.

JIPIC Amicus Filings:

• JIPIC Blog post about the brief
• Amici Brief of HIV Organizations
• Motion for Leave to File the Amici Brief

Federal Trade Commission Amicus Filings

• FTC Amicus Brief

• FTC Motion for Leave to File Amicus Brief

Plaintiffs’ Opposition to Motions to Dismiss

• Brief in Opposition

Defendants’ Motions to Dismiss the Complaint:

• Gilead Sciences, Inc.
• Bristol-Myers Squibb
• Johnson & Johnson
• Japan Tobacco

Gilead Agreements with Other defendants (redacted versions as filed on the court docket by Gilead)

• Gilead and Bristol-Myers Squibb Collaboration Agreement (Dec. 17, 2004)
• Gilead and Bristol-Myers Squibb Duo License Agreement (October 25, 2011)
• Gilead and ER Squibb Manufacturing and Supply Agreement (December 17, 2004)
• Gilead and Janssen R&D Ireland Collaboration Agreement (for Complera and the R/F/TAF product) (Dec. 23, 2014)
• Gilead and Janssen R&D Ireland Collaboration Agreement (for DRV, TAF, COBI and FTC) (Dec. 23, 2015)
• Gilead and Japan Tobacco License Agreement (March 22, 2005)

Corrected Consolidated Class Action Complaint (filed Aug. 22, 2019)

Juelsgaard Clinic homepage

Amicus brief FAQs